Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant

Author:

Shockley Abigail1ORCID,Davis James A1ORCID,Gaffney Kelly J1ORCID,Smith Deidra1,Weeda Erin2,Hashmi Hamza3ORCID

Affiliation:

1. Medical University of South Carolina Department of Pharmacy, Charleston, SC, USA

2. Medical University of South Carolina College of Pharmacy, Charleston, SC, USA

3. Division of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, SC, USA

Abstract

Background For transplant-eligible newly diagnosed multiple myeloma patients, autologous hematopoietic stem cell transplant followed by maintenance lenalidomide is a standard of care practice. Maintenance lenalidomide dosing practices vary amongst physicians and current literature lacks comparisons on intermittent versus continuous dosing. In this retrospective study, we compared the safety, tolerability, and efficacy of continuous versus intermittent lenalidomide dosing. Methods This single-center, retrospective review included 72 patients with multiple myeloma receiving lenalidomide maintenance between 2018 and 2021. The primary objective was to determine the incidence of dose modification, defined as any dosage reduction, delay in treatment, or discontinuation of therapy. The secondary objectives were to determine the incidence of hematological and non-hematological toxicities between the two groups. Results A total of 58 patients in the continuous group and 14 patients in the intermittent group were included. Fifty-four percent of patients in the continuous group required dose modification versus 30% in the intermittent group. Patients who received continuous dosing appeared to have a higher incidence of adverse events when compared to intermittent dosing with the most common adverse events being neutropenia, fatigue, and rash. Twenty-four patients in the continuous group switched to an intermittent schedule after an adverse event. Of these patients, only 8% required further dose modification. Conclusion The higher incidence of lenalidomide dose modifications in the continuous arm suggests that a majority of patients are not able to tolerate continuous lenalidomide maintenance. A more tolerable option for maintenance may be an intermittent schedule, as reflected by the favorable safety outcomes in this group.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Reference11 articles.

1. Multiple Myeloma

2. Cancer Statistics, 2021

3. Myeloma - Cancer Stat Facts. SEER, https://seer.cancer.gov/statfacts/html/mulmy.html (accessed 1 October 2021).

4. National Comprehensive Cancer Network. Multiple myeloma (version 4.2021), www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 1 October 2021).

5. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3